KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $487000.0.

  • Travere Therapeutics' Other Non Operating Income fell 634.62% to $487000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$71000.0, marking a year-over-year increase of 9479.09%. This contributed to the annual value of -$3.3 million for FY2024, which is 30815.56% down from last year.
  • Per Travere Therapeutics' latest filing, its Other Non Operating Income stood at $487000.0 for Q3 2025, which was down 634.62% from -$526000.0 recorded in Q2 2025.
  • Travere Therapeutics' 5-year Other Non Operating Income high stood at $1.4 million for Q4 2023, and its period low was -$7.6 million during Q1 2022.
  • Over the past 5 years, Travere Therapeutics' median Other Non Operating Income value was $162500.0 (recorded in 2023), while the average stood at -$448166.7.
  • As far as peak fluctuations go, Travere Therapeutics' Other Non Operating Income skyrocketed by 47748.69% in 2021, and later tumbled by 163880.6% in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Other Non Operating Income stood at -$860000.0 in 2021, then skyrocketed by 31.86% to -$586000.0 in 2022, then surged by 334.47% to $1.4 million in 2023, then crashed by 142.29% to -$581000.0 in 2024, then soared by 183.82% to $487000.0 in 2025.
  • Its Other Non Operating Income was $487000.0 in Q3 2025, compared to -$526000.0 in Q2 2025 and $549000.0 in Q1 2025.